QCP: If institutions like Strategy and Metaplanet reduce their purchasing efforts, it may reverse the current BTC upward trend
On May 21, according to QCP Capital's analysis, Bitcoin attempted to break through the $108,000 level today but failed, primarily due to a lack of sustained buying momentum. The current price trend is closely related to the buying behavior of the two major institutions, Strategy and Metaplanet, which remain the main buyers at the current price level. The analysis points out that the market is concerned these institutions may be the last marginal buyers, especially as Bitcoin approaches historical highs. If these institutions reduce their purchasing power, it could trigger profit-taking by other market participants and potentially reverse the current upward trend. QCP Capital notes that despite adverse factors such as rising bond yields, increased tariffs, and the risk of stagflation in the U.S. economy, Bitcoin has shown strong resilience over the past month. If it breaks new highs, it could trigger a new round of buying, bringing in off-market funds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening
According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).
Chevron has suspended production operations at five facilities in the U.S. Gulf region.
Chevron (CVX.US) has evacuated personnel and shut down production operations at five facilities in the US Gulf region, while another four offshore platforms continue production.
Chevron deploys related technology to protect Gulf of Mexico coastal business facilities
Chevron (CVX.US): Deployed relevant technologies to protect Gulf Coast business facilities during Hurricane Isaias.
Crypto prices
More
